Peptide content is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-03. Numbers and descriptions here follow the published literature rather than marketing material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
The use of antioxidants to prevent some diseases is controversial. In a high-risk group like smokers, high doses of beta carotene increased the rate of lung cancer since high doses of beta-carotene in conjunction with high oxygen tension due to smoking results in a pro-oxidant effect and an antioxidant effect when oxygen tension is not high. In less high-risk groups, the use of vitamin E appears to reduce the risk of heart disease. However, while consumption of food rich in vitamin E may reduce the risk of coronary heart disease in middle-aged to older men and women, using vitamin E supplements also appears to result in an increase in total mortality, heart failure, and hemorrhagic stroke. The American Heart Association therefore recommends the consumption of food rich in antioxidant vitamins and other nutrients, but does not recommend the use of vitamin E supplements to prevent cardiovascular disease. In other diseases, such as Alzheimer's, the evidence on vitamin E supplementation is also mixed. Since dietary sources contain a wider range of carotenoids and vitamin E tocopherols and tocotrienols from whole foods, ex post facto epidemiological studies can have differing conclusions than artificial experiments using isolated compounds. The nitrone radical scavenger NXY-059 was investigated for acute ischemic stroke, but a large phase III trial failed to confirm its efficacy.
In 2004, John L. Helgerson, the Inspector General of the Central Intelligence Agency (CIA), conducted an internal review of the agency's pre-9/11 performance and was harshly critical of senior CIA officials for not doing everything possible to confront terrorism. According to Philip Giraldi in The American Conservative, Helgerson criticized their failure to stop two of the 9/11 hijackers, Nawaf al-Hazmi and Khalid al-Mihdhar, as they entered the United States and their failure to share information on the two men with the FBI. In May 2007, senators from both major U.S. political parties (the Republican and Democratic parties) drafted legislation to make the review public. One of the backers, Senator Ron Wyden said, "The American people have a right to know what the Central Intelligence Agency was doing in those critical months before 9/11." The report was released in 2009 by President Barack Obama.
The seeds are spherical or broadly elliptical, and are up to 0.5 mm (1⁄64 in) long with a wavy networked surface. Almost every part of the plant except the seed contains nicotine, but the concentration is related to different factors such as species, type of land, culture and weather conditions. The concentration of nicotine increases with the age of the plant. Tobacco leaves contain 2-to-8% nicotine combined as malate or citrate. The distribution of the nicotine in the mature plant is widely variable: 64% of the total nicotine exists in the leaves, 18% in the stem, 13% in the root, and 5% in the flowers.
== Pharmacokinetics == Valsartan has an oral bioavailability of approximately 25% and reaches peak blood concentrations around 2–4 hours after ingestion. The estimated elimination half-life is determined to be approximately 6 hours, volume distribution of 17 litres, and a protein binding of 95% is seen. The elderly may see increases in half life of the drug by up to 35% but dosing adjustment will not typically be warranted, however the drug should be used with caution in severe liver or kidney impairment. Majority of the drug is eliminated through the feces (83%) while only a small portion is eliminated in the urine (13%). Most of the drug excreted is unchanged, only small portion of the drug is metabolized to its inactive form 4-hydroxyvaleryl valsartan, the enzyme suspected to be responsible for this is the liver enzyme CYP2C9. Hydrochlorothiazide has an oral bioavailability of 70% and reaches peak concentration around 1.5–2 hours following ingestion. The half-life is quite variable for this drug and can range from 5–15 hours. This drug is not metabolized and is mostly excreted unchanged in the urine (60-70%). Protein binding ranges between 40 and 70% and volume of distribution varies from 4-8L/kg.
The Scottish Government had wanted it delayed until after a separate hearing into determining the definition of a woman. 6 August – Five people are arrested when protestors interrupt the Men's Elite Road Race at Falkirk. The environmental protest group This Is Rigged claims responsibility. 7 August – Police Scotland confirms that the bodies of three hillwalkers have been found after they failed to return from a trip to Aonach Eagach Ridge in Glen Coe two days earlier. Education staff at ten local authorities who belong to the Unite union vote to take rolling industrial action after rejecting a pay offer from the Scottish Government. 8 August – Jamie Starrs is sentenced to ten and a half years in prison for the rape of Amber Gibson in June 2021, five months before she was murdered by her brother. 9 August – The names of several thousand people adopted as children going back 100 years are removed from the ScotlandsPeople website amid concerns over privacy and safety. 10 August – Social Security Scotland issues an apology over a staff quiz that included pictures of child killers. The Friday Fun Quiz asked staff to identify people called Ian from images, and includes pictures of Ian Brady and Ian Huntley. 11 August – At the High Court in Stirling, James White, the leader of one of Scotland's largest organised crime gangs who was extradited from Brazil to face trial, is sentenced to ten years in prison for series organised crime and firearms offences. 12 August – Police Scotland announces plans to cut civilian staff and freeze recruitment in order to maintain officer numbers.
Sources: en.wikipedia.org
Long before the born secret issues associated with the restricted data provisions of the US Atomic Energy Act of 1946, the US Invention Secrecy Act of 1951, and the US Patent and Trademark Law Amendments Act of 1980 and/or the increasing concerns with respect to the on-going biopiracy of natural products, and in the early 20th-century atmosphere of cultural change — not only in the proliferation of vocational universities, rather than research universities, but also in the gradual move from the disciplinary concentration on "pure science" and, perhaps, aspects of "applied science", to that of fostering "industrial science" in both primary and secondary industries — the ethical question of whether or not those universities devoted to "pure science" (viz., the discovery/creation, distillation, refinement, diffusion, and the free dissemination of knowledge for the benefit of the public) should have any interest in "applied science", and further, whether they should have any commercial interest in the products of their research and, in particular, whether they should seek patents for their discoveries. In his 1926 Presidential address to the Society of American Bacteriologists (HZ.1), Hans Zinsser spoke against "the growing tendency on the part of medical scientific workers, and bacteriologists especially, to patent discoveries of practical therapeutic and public health value" (p.157).
=== Ho–Hu === Gladys Lounsbury Hobby (1910–1993), American microbiologist known for development and early understanding of antibiotics Dorothy Hodgkin (1910–1994), British chemist, 1964 Nobel Prize in chemistry for development of protein crystallography Jacobus Henricus van 't Hoff (1852–1911), Dutch physical chemist known for developing the princioles of chemical thermodynamics, 1901 Nobel Prize in Chemistry Albert Hofmann (1906–2008), Swiss chemist, synthesized Lysergic acid diethylamide (LSD) August Wilhelm Hofmann (1818–1892), German chemist, first to isolate sorbic acid Darleane C. Hoffman (1926–2025), American nuclear chemist who studied the properties of transuranium elements Friedrich Hoffmann (1660–1742), German physician and chemist who found that lime, magnesia, etc. existed in almost all mineral springs in Germany Roald Hoffmann (born 1937), Polish-born American chemist, 1981 Nobel Prize in Chemistry for theories of the course of chemical reactions Antonín Holý (1936–2012), Czech medicinal chemist known for acyclic nucleoside phosphonates, including Cidofovir, Adefovir and Tenofovir Mei Hong (born 1970), Chinese-American biophysical chemist known for development solid-state nuclear magnetic resonance to elucidate the structures and mechanisms of membrane proteins Frederick Gowland Hopkins (1861–1947), British biochemist, known for discovery of vitamins, Nobel Prize in Physiology or Medicine in 1929 Marjorie G.
Pulmonary fibrosis is typically a condition in which the lungs become scarred over time. Symptoms include shortness of breath, a dry cough, feeling tired, weight loss, and nail clubbing. Complications may include pulmonary hypertension, respiratory failure, pneumothorax, and lung cancer. Causes include environmental pollution, certain medications, connective tissue diseases, infections, and interstitial lung diseases. But in most cases the cause is unknown (idiopathic pulmonary fibrosis). Diagnosis may be based on symptoms, medical imaging, lung biopsy, and lung function tests. No cure exists and treatment options are limited. Treatment is directed toward improving symptoms and may include oxygen therapy and pulmonary rehabilitation. Certain medications may slow the scarring. Lung transplantation may be an option. At least 5 million people are affected globally. Life expectancy is generally less than five years following diagnosis.
== Risk factors == Adolescents are the most vulnerable group when it comes to taking performance-enhancing substances. This is in part due to the significance placed on physical appearance by this age group as well as feelings of invincibility combined with a lack of knowledge surrounding long-term consequences. Studies have shown that the most common gendered risk factors include being an adolescent female dissatisfied with their body weight or an adolescent male who perceives larger body sizes as the ideal. Having a negative body image or a history of depression can also be a significant risk factor. These are further exacerbated by parental pressures surrounding appearance, media influence, and peer pressure. Studies show that adolescent males who engage with fitness magazines are twice as likely to use performance-enhancing substances. Adolescents who partake in competitive sports are at a particularly high risk, with those involved in gridiron football, basketball, wrestling, baseball, and gymnastics at the top.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.